PharmEcology® Provides Disposal Guidelines for the 2017-2018 Flu Season
PharmEcology, a division of WM Sustainability Services, is pleased to publish a summary of the proper flu vaccine disposal guidelines for the 2017-2018 flu season as a public service to the healthcare community. According to the CDC, it is expected that flu vaccine manufacturers will supply up to 151 to 166 million doses (e.g. inactivated and recombinant flu vaccines) of the injectable vaccine for the U.S. market, although these projections may change as the season progresses.
Relevant 2017-2018 flu season facts include: (1) only the injectable form of flu vaccine is recommended this season, (2) live attenuated influenza vaccine (LAIV4) (e.g. FluMist Quadrivalent intranasal) is not recommended this year, and (3) flu vaccines are updated to reflect the applicable viruses in the 2017-2018 season. For extensive information about the flu vaccine, please visit the CDC website.
Frequently Asked Questions (FAQs) regarding flu vaccine disposal:
What does this guidance provide?
Flu vaccine, including unused or partial vials, should be disposed of inaccordance with applicable federal, state, and local regulations. For the purposes of this webpage, the guidance provided is to address the Resource Conservation & Recovery Act (RCRA) waste categorization requirement as it applies to flu vaccine waste. You should always check all applicable regulations, including your state and local regulations to ensure full compliance and/or please feel free to contact PharmEcology for additional information at firstname.lastname@example.org or by calling 877-247-7430.
How does the regulation (RCRA) apply to the flu vaccine?
Some of the flu vaccine products contain a preservative called thimerosal which is a mercury-based preservative which has been used for decades in the United States to prevent germ growth in multi-dose vials of vaccines. Under 40 CFR Part 261.24 if the waste contains one or more constituents at concentrations greater than those specified in the maximum concentration of contaminants for the toxicity characteristic, the waste is considered hazardous. The D009 toxicity characteristic applies for mercury-containing waste when the concentration exceeds the 0.2mg/L threshold (0.2 mg/L = 0.2 mcg/mL). Any flu vaccine containing thimerosal or for which thimerosal was used in the processing will also designate as a hazardous waste, D009.
The flu vaccine that we used is not hazardous. How do I dispose of it?
Flu vaccine waste that does not meet the definition of a hazardous waste under the Resource Conservation and Recovery Act (RCRA) may be disposed of with your other non-hazardous pharmaceutical waste, but you must consider your applicable state or local regulations. . In addition, if a flu vaccine product contains live attenuated virus, such as FluMist, should be disposed of as biohazardous. FluMist is not specifically listed in the chart below since it is not approved for the 2017-2018 season. If you do not have a pharmaceutical waste procedure, please contact us for additional information.
The flu vaccine that we used is hazardous. How do I dispose of it?
If you have determined that your flu vaccine waste is hazardous, you must dispose of it as a hazardous waste. This includes appropriately segregating and managing it as a hazardous waste in your facility. This does not mean placing it in a red sharps container, or another trash container. Please feel free to contact us if you need additional information.
How do we dispose of flu vaccine that is hazardous and also biohazardous?
In the rare instance that it is necessary to dispose of a full or partially used sharp syringe containing a vaccine with thimerosal, the sharp should be disposed of as dual hazardous and biohazardous waste. An unused vaccine in a vial cannot be both hazardous and biohazardous, as the thimerosal would kill the active virus.
Where may I find more information?
- For information on the flu, visit the CDC website at https://www.cdc.gov/flu/index.htm.
- For information on the flu vaccine including a table listing of all available forms of the vaccine for the 2017-2018 season, please see the table below or visit the CDC website references listed below.
- For additional information on proper disposal of all pharmaceutical waste: please contact us at email@example.com or by calling 1-877-247-7430.
Flu vaccine summary table:
The table below summarizes the waste categorizations of the specific products available this season. Applying the federal regulation to the flu vaccines, the vaccines meet the toxicity characteristic when the concentration of mercury is equal to or greater than 0.2mg/liter as a result of performing a test known as the toxicity characteristic leaching procedure (TCLP).
While we do not have results for such tests for vaccines, a calculation of the concentration of mercury in vaccines in which thimerosal is present as a preservative would cause the waste vaccine to fail the TCLP. Unless a manufacturer provides actual TCLP data indicating the mercury level to be below 0.2mg/liter or a healthcare facility has the test performed and the waste does not fail the TCLP, any vaccine waste containing thimerosal as a preservative should be managed as a toxic hazardous waste. As a result, all full or partially used multi-dose vials of the seasonal flu vaccine should be disposed of as federally hazardous waste, waste code D009.
|Trade name||Manufacturer||NDC||Size||Mercury content ug/0.5ml (in the form of thimerosal preservative)||Categorization||Date of published package insert|
|Afluria||Seqirus||Single dose prefilled syringe (NDC 33332-017-01) Ten 0.5 mL single-dose syringes (NDC 33332-017-02)||0.5 mL prefilled syringe (single dose)||No preservatives||Non-hazardous||March 2017|
|Afluria||Seqirus||5 mL multi-dose vial (NDC 33332-117-10) One 5 mL vial, which contains ten 0.5 mL doses (NDC 33332-117-11)||5 mL multi-dose vial (ten 0.5 mL doses)||Each 0.5 mL dose contains 24.5 mcg of mercury (in the form of thimerosal)||Hazardous, D009||March 2017|
|Afluria Quadrivalent||Seqirus||Single dose prefilled syringe (NDC 33332-317-01) Ten 0.5 mL single-dose syringes (NDC 33332-317-02)||0.5 mL prefilled syringe (single dose)||No preservatives||Non-hazardous||July 2017|
|Afluria Quadrivalent||Seqirus||5 mL multi-dose vial (NDC 33332-417-10) One 5 mL vial, which contains ten 0.5 mL doses (NDC 33332-417-11)||5 mL multi-dose vial (ten 0.5 mL doses)||Each 0.5 mL dose contains 24.5 mcg of mercury (in the form of thimerosal)||Hazardous, D009||July 2017|
|Flulaval Quadrivalent||GlaxoSmithKline||Single dose prefilled syringe (NDC 19515-912-41) Syringe in package of 10: (NDC 19515-912-52)||0.5-mL single-dose prefilled syringes||No preservatives||Non-hazardous||April 2017|
|Flulaval Quadrivalent||GlaxoSmithKline||5 mL multi-dose vial (NDC 19515-896-01) Multi-Dose Vial (containing 10 doses) in package of 1: (NDC 19515-896-11)||5-mL multi-dose vials containing 10 doses (each dose is 0.5 mL).||Each 0.5 mL dose from the MDV contains <25 mcg mercury (in the form of thimerosal)||Hazardous, D009||April 2017|
|Fluzone Quadrivalent||Sanofi Pasteur Inc.||Suspension for injection supplied in 4 presentations: prefilled single-dose syringe (pink plunger rod), 0.25 mL; (NDC 49281-517-00). Supplied as package of 10 (NDC 49281-517-25)||Suspension for injection supplied in 4 presentations: prefilled single-dose syringe (pink plunger rod), 0.25 mL; prefilled single-dose syringe (clear plunger rod), 0.5 mL; single-dose vial, 0.5 mL; multi-dose vial, 5 mL.||No preservatives||Non-hazardous||July 2017|
|Prefilled single-dose syringe (clear plunger rod), 0.5 mL; (NDC 49281-417-88). Supplied as package of 10 (NDC 49281-417-50)||No preservatives||Non-hazardous||July 2017|
|Single-dose vial, 0.5 mL; (NDC 49281-417-58) Supplied as package of 10 (NDC 49281-417-10)||No preservatives||Non-hazardous||July 2017|
|Fluzone Quadrivalent||Sanofi Pasteur Inc.||Multi-dose vial, 5 mL (NDC 49281-627-78). Supplied as package of 1 (NDC 49281-627-15)||Each 0.5 mL dose from the MDV contains 25 mcg mercury and each 0.25 mL dose from the MDV contains 12.5 mcg mercury (in the form of thimerosal)||Hazardous, D009||July 2017|
|Fluarix Quadrivalent||GlaxoSmithKline||NDC 58160-907-41 Syringe in package of 10: (NDC 58160-907-52)||0.5 mL needleless prefilled syringe||No preservatives||Non-hazardous||April 2017|
|Fluzone High- Dose||Novartis||Single-dose, prefilled syringe, without needle, 0.5 mL (NDC 49281-401-88) Supplied as package of 10 (NDC 49281-401-65).||Suspension for injection in prefilled syringe (gray plunger rod), 0.5 mL||No preservatives||Non-hazardous||July 2017|
|Fluvirin||Seqirus||0.5 mL single dose pre-filled syringe (NDC 70461-120-02) Package of 10 syringes per carton (may contain latex) (NDC 70461-120-12)||0.5 mL single-dose prefilled syringe||No preservative, but thimerosal is in trace amounts due to manufacturing process (≤ 1 mcg mercury per 0.5 mL dose)||Hazardous, D009||March 2017|
|Flucelvax Quadrivalent||Seqirus||0.5 mL single dose pre-filled syringe (NDC 70461-201-01) Package of 10 syringes per carton (NDC 70461-201-11)||0.5 mL single dose pre-filled syringe||No preservative||Non-hazardous||April 2017|
|Flucelvax Quadrivalent||Seqirus||5 mL multi-dose vial (NDC 70461-301-10) Individually packaged in a carton (NDC 70461-301-12)||5 mL multi-dose vial||Each 0.5 mL dose from the MDV contains 25 mcg mercury (in the form of thimerosal)||Hazardous, D009||April 2017|
|Flublok Quadrivalent||Protein Sciences||Single-dose, 0.5 mL syringe in a 5 or 10 syringe carton. Single syringe: (NDC 42874-117-10) Carton of 10: (NDC 42874- 117-01)||Single-dose, 0.5 mL syringe in a 5 or 10 syringe carton||No preservatives||Non-hazardous||March 2017|
|Flublok||Protein Sciences||Single-dose, 0.5 mL vial in a 10 vial carton. (NDC 42874-017-10)||Single-dose, 0.5 mL vial in a 10 vial carton.||No preservatives||Non-hazardous||March 2017|
|Fluad||Seqirus||0.5 mL pre-filled needleless syringe: package of 10 pre-filled syringes per carton (NDC number: 70461-002-01) Pre-filled single syringe (NDC number: 70461-002-11)||0.5 mL pre-filled needleless syringe:||No preservatives||Non-hazardous||March 2017|
- “Frequently Asked Flu Questions 2017-2018 Influenza Season.” CDC.gov. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD), 11 Apr. 2017. Web. 7 Sep. 2017. <https://www.cdc.gov/flu/about/season/flu-season-2017-2018.htm>.
- "Seasonal Influenza Vaccination Resources for Health Professionals.” CDC.gov. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD), 25 Aug. 2017. Web. 7 Sep. 2017.<https://www.cdc.gov/flu/professionals/vaccination/index.htm>.
- “Prevention and Control of Seasonal Influenza with Vaccines.” CDC.gov. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD), 24 Aug. 2017. Web. 7 Sep. 2017. <https://www.cdc.gov/flu/professionals/acip/index.htm>.
- “2017-18 Summary of Recommendations.” CDC.gov. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD), 24 Aug. 2017. Web. 7 Sep. 2017. <https://www.cdc.gov/flu/professionals/acip/2017-18summary.htm>.
- “Seasonal Influenza Vaccine Supply for the U.S. 2017-2018 Influenza Season.” CDC.gov. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD), 30 Aug. 2017. Web. 7 Sep. 2017. <https://www.cdc.gov/flu/about/qa/vaxsupply.htm>.
- “Influenza Virus Vaccine for the 2017-2018 Season.”FDA.gov. U.S. Food and Drug Administration, 7 Sep. 2017. Web.7 Sep. 2017. <https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm567865.htm>.
 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094043.htm and https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM263239.pdf
 https://www.fda.gov/downloads/.../Vaccines/ApprovedProducts/UCM404086.pdf and https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Flulaval_Quadrivalent/pdf/FLULAVAL-QUADRIVALENT.PDF
 https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm220624.pdf and https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Fluarix_Quadrivalent/pdf/FLUARIX-QUADRIVALENT.PDF
- Posted: September 14, 2017
Rely on our Sustainable Pharmacy® solutions to deliver environmentally sound management of both hazardous and non-hazardous pharmaceutical waste.
PharmEcology has been the thought leader in pharmaceutical waste management since its inception in 2000 and has pioneered both hazardous waste categorization and the implementation process throughout the healthcare organization.